SCHEMBL22122984

SCHEMBL22122984

CCc1cc(Nc2nccn3c(-c4ccc(OC)c(F)c4F)cnc23)ccc1C(=O)NCC(=O)NCCN

nearest known ligand 0.36

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 6/20 0.36
▸ MAPKAPK5 Q8IW41 1/20 0.35
▸ AXL P30530 2/20 0.34
▸ PTK6 Q13882 1/20 0.34
▸ ZAP70 P43403 2/20 0.33
▸ KARS1 Q15046 2/20 0.33
▸ TTK P33981 5/20 0.33
▸ IDO1 P14902 2/20 0.33
▸ IGF1R P08069 1/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30171593 1.00 SYK (0.36) SYKMAPKAPK5AXLPTK6ZAP70
SCHEMBL22122926 0.95 SYK (0.38) SYKMAPKAPK5AXLPTK6ZAP70
Hydrochloric Acid SCHEMBL22123655 0.94 SYK (0.37) SYKMAPKAPK5AXLPTK6ZAP70
Hydrochloric Acid SCHEMBL22123235 0.94 SYK (0.37) SYKMAPKAPK5AXLPTK6ZAP70
SCHEMBL30171808 0.94 PTK6 (0.35) SYKMAPKAPK5AXLPTK6ZAP70
SCHEMBL22123448 0.94 PTK6 (0.35) SYKMAPKAPK5AXLPTK6ZAP70
SCHEMBL30171810 0.93 PTK6 (0.34) SYKMAPKAPK5AXLPTK6TTK
SCHEMBL22123242 0.93 PTK6 (0.34) SYKMAPKAPK5AXLPTK6TTK
SCHEMBL22123399 0.92 SYK (0.36) SYKMAPKAPK5AXLPTK6ZAP70
SCHEMBL30171950 0.92 SYK (0.36) SYKMAPKAPK5AXLPTK6ZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3898631-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS HOFFMANN LA ROCHE (CH) 2023-01-18 — — EP claimed
US-20230012368-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-12 — — US claimed
EP-3898631-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS F. Hoffmann-La Roche AG (CH) 2021-10-27 — — EP claimed
WO-2020126953-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS F. HOFFMANN-LA ROCHE AG (CH) 2020-06-25 — — WO claimed
US-20230012368-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-12 — — US disclosed
US-20230012368-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230012368-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, MYD88, IL1R1 SYK 954/4885MAPKAPK5 647/4885AXL 2849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback